The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
about
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomesThe transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypesRetinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategiesThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisRB1: a prototype tumor suppressor and an enigmaMolecular mechanisms underlying RB protein functionUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastomaRetinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsTherapeutic targeting of replicative immortalityDifferential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell modelTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingFunctional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cellsJnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest.Regulation of hormonal therapy resistance by cell cycle machinery.Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.Role of autophagy in breast cancer.Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.Interaction between cartilage oligomeric matrix protein and extracellular matrix protein 1 mediates endochondral bone growth.ERK/MAPK regulates ERRĪ³ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.Adjusting for misclassification in a stratified biomarker clinical trial.Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancersPalbociclib: an evidence-based review of its potential in the treatment of breast cancerTailoring to RB: tumour suppressor status and therapeutic response.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developmentsANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.Targeting Rb inactivation in cancers by synthetic lethality.RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Regulation of mitotic cytoskeleton dynamics and cytokinesis by integrin-linked kinase in retinoblastoma cells.Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cellsRB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
P2860
Q21195193-3F94E889-AE5B-4BA3-A2F4-63908DAA2C5CQ24617123-1B0E2DBE-0E13-4747-BF19-AB8E077C6545Q26750380-A09FDCFB-55E1-470F-9827-66EC9845CCDFQ26782449-30CD27FC-B949-4B94-9488-7B34426867ACQ26865888-89AA0D18-43B8-4EB0-9D1A-D4E01A98AAD4Q26866393-C01F50DC-DEAA-497B-AB4C-1A0A8A4426EEQ27003956-4EB1961F-A276-48F3-BB53-6A25619FE869Q27011911-A48B7BC1-2CA3-41DA-89EB-CC3D13B1CE54Q27022834-C98799F6-576F-4B7E-A1B8-7B55A0EC8200Q27027457-808BA5EB-4F68-4F00-BB4F-4176F78F1780Q28472388-42FAC13B-25EB-4F70-A304-1B9B4A859BD3Q30419997-1BCA9D5F-9504-4700-8ECA-F505AEBCF8ADQ31132241-0D7C3E21-7527-452E-AC5E-3EE12C4CBD1BQ33308716-2A3FFD9D-7E90-40BD-B7D5-91585227D29AQ33573421-FB0C7AF7-3D56-4A06-BED4-EEBF643637B6Q33588743-9A75D44A-F42D-4852-B386-C1D8D74BB20DQ33615259-51102031-6079-4A99-ACEB-9E6FA603517DQ33635621-FAD091E5-D55A-448B-8E57-A3C52DF0788EQ33731365-6E69EEDC-3D1A-4D96-92E2-65B44F6E3149Q33788520-38D4ED4F-3FFC-4322-827B-3BF7720298B2Q33808483-A2F649CE-C7D3-40CE-9906-889EB0BD9D82Q33812043-0F41489D-5426-4CF4-838C-AE3A0B371CA2Q33823788-D521A810-02A4-4CA2-B5FA-3ADB85F7070AQ33836140-72FFD373-A45E-4EB2-B7FD-5241D713C0EAQ33934232-AD0752BF-5E14-4230-93F3-2FB0AE0ED7E5Q34013967-4F2EC604-A34F-432F-A05F-B6AF399F232FQ34027724-2AB73D8B-6CA9-4F0D-B65B-2EFDE021119BQ34040108-72DFC4FC-4BFF-46AC-9ABE-FCD633E6E628Q34147910-044156C5-C01C-4E43-860C-9B8DB44E2E12Q34202289-6785C1ED-4881-4296-80B8-5DF32389D8C0Q34316094-A2314D80-EB57-4B5C-986F-824D52757FA8Q34394399-0C201925-25EA-4DF5-A1EF-764BD5D800B9Q34659897-FD935323-83B3-48A5-AB9A-28A9C9D4108EQ34984068-CBB9DB93-9480-4380-A97B-421329B721B4Q35050328-BEBDBDE1-EBA1-43B2-9E56-97581D79B703Q35138543-9F3FBF8E-E7C1-4B68-B110-D1609B87C6F4Q35157633-BA8920B4-B6CC-489E-9BCF-213877E00A84Q35184072-2214ED65-E4C0-4DB0-956C-A201C7EA0C9AQ35558138-BBCE4828-FFAD-451A-933E-18497918C19BQ35620241-5131A5FE-9CC6-4F38-ADC8-70A5B7E18592
P2860
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō“Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2006 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ¤Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
name
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@ast
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@en
type
label
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@ast
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@en
prefLabel
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@ast
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@en
P2093
P2860
P356
P1476
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
@en
P2093
Emily E Bosco
Erik S Knudsen
Jack T Zilfou
Scott W Lowe
P2860
P304
P356
10.1172/JCI28803
P407
P577
2006-12-07T00:00:00Z